Collins, JJ, Baase, CM, Sharda, CE, et al. The assessment of chronic health conditions on work performance, absence, and total economic impact for employers. J Occup Environ Med. 2005; 47(6): 547–557.
Greenberg, PE, Fournier, A-A, Sisitsky, T, et al. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015; 76(2): 155–162.
Greenberg, PE, Kessler, RC, Birnbaum, HG, et al. The economic burden of depression in the United States: How did it change between 1990 and 2000? J Clin Psychiatry. 2003; 64(12): 1465–1475.
Lam, RW, McIntosh, D, Wang, J, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 1. Disease burden and principles of care. Can J Psychiatry. 2016; 61(9): 510–523.
Patten, SB, Williams, JV, Lavorato, DH, et al. Descriptive epidemiology of major depressive disorder in Canada in 2012. Can J Psychiatry. 2015; 60(1): 23–30.
Lim, K-L, Jacobs, P, Ohinmaa, A, et al. A new population-based measure of the economic burden of mental illness in Canada. Chronic Dis Can. 2008; 28(3): 92–98.
Stonebridge, C, Sutherland, G. Healthy Brains at Work: Estimating the Impact of Workplace Mental Health Benefits and Programs. The Conference Board of Canada, 1, 2016.
Lam, RW, Kennedy, SH, McIntyre, RS, et al. Cognitive dysfunction in major depressive disorder: Effects on psychosocial functioning and implications for treatment. Can J Psychiatry. 2014; 59(12): 649–654.
Conradi, HJ, Ormel, J, de Jonge, P. Presence of individual (residual) symptoms during depressive episodes and periods of remission: A 3-year prospective study. Psychol Med. 2011; 41(6): 1165–1174.
Fava, M, Graves, LM, Benazzi, F, et al. A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. J Clin Psychiatry. 2006; 67(11): 1754.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5®). American Psychiatric Pub, United States; 2013.
Thase, ME, Mahableshwarkar, AR, Dragheim, M, et al. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults. Eur Neuropsychopharmacol : J Eur Coll Neuropsychopharmacol. 2016; 26(6): 979–993.
Cipriani, A, Furukawa, TA, Salanti, G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet (London, England). 2018; 391(10128): 1357–1366.
Alvarez, E, Perez, V, Dragheim, M, et al. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol. 2012; 15(5): 589–600.
Baldwin, DS, Loft, H, Dragheim, M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol. 2012; 22(7): 482–491.
Boulenger, J-P, Loft, H, Florea, I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol. 2012; 26(11): 1408–1416.
Jain, R, Mahableshwarkar, AR, Jacobsen, PL, et al. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol. 2012; 16(2): 313–321.
Katona, C, Hansen, T, Olsen, CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012; 27(4): 215–223.
Mahableshwarkar, AR, Jacobsen, PL, Chen, Y. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin. 2013; 29(3): 217–226.
Kennedy, SH, Lam, RW, McIntyre, RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 3. Pharmacological treatments. Can J Psychiatry. 2016; 61(9): 540–560.
Chokka, P, Bougie, J, Rampakakis, E, et al. Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD). CNS Spectr. 2018; 1–10. doi:10.1017/s1092852918000913
Chokka, P, Bougie, J, Proulx, J, et al. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study. CNS Spectr. 2019; 1–12. doi:10.1017/S1092852919000786
Despiegel, N, Danchenko, N, Francois, C, et al. The use and performance of productivity scales to evaluate presenteeism in mood disorders. Value Health. 2012; 15(8): 1148–1161.
Lerner, D, Amick, III Rogers, BC , WH, et al. The work limitations questionnaire. Med Care. 2001; 39(1): 72–85.
Lofland, JH, Pizzi, L, Frick, KD. A review of health-related workplace productivity loss instruments. Pharmacoeconomics. 2004; 22(3): 165–184.
Lundbeck Canada Inc. Vortioxetine—Product monograph. Updated July 8th 2016. 2016.
Vieta, E, Loft, H, Florea, I. Effectiveness of long-term vortioxetine treatment of patients with major depressive disorder. Eur Neuropsychopharmacol. 2017; 27(9): 877–884. doi:10.1016/j.euroneuro.2017.06.012
Kessler, RC, Akiskal, HS, Ames, M, et al. Prevalence and effects of mood disorders on work performance in a nationally representative sample of US workers. Am J Psychiatry. 2006; 163(9): 1561–1568.
Romera, I, Perez, V, Menchón, J, et al. Social and occupational functioning impairment in patients in partial versus complete remission of a major depressive disorder episode. A six-month prospective epidemiological study. Eur Psychiatry. 2010; 25(1): 58–65.
Van den Hout, W. The value of productivity: Human-capital versus friction-cost method. Ann Rheum Dis. 2010; 69(Suppl 1): i89–i91.